Centella asiatica extract
Centella asiatica extract is an orally active herbal extract. Centella asiatica extract scavenges free radicals, increases stratum corneum hydration, improves epidermal barrier function, and reduces skin redness and skin pH. Centella asiatica extract inhibits pro-inflammatory cytokines, suppresses p38 MAPK phosphorylation, reduces mast cell infiltration, and decreases the expression of TNF-α, IL-4, IL-5, IL-6, IL-17, CXCL9, iNOS and COX-2. Centella asiatica extract upregulates the expression of BDNF and downregulates the expression of VGLUT1, and exhibits neuroprotective effects under hypoxic conditions. Centella asiatica extract inhibits pro-inflammatory M1 macrophage polarization and prevents adipose tissue senescence. Centella asiatica extract can be used in studies related to hypoxia-induced neurological dysfunction, atopic dermatitis, and obesity-induced insulin resistance.
For research use only. We do not sell to patients.
- CAS No.: 84696-21-9
-
Storage:
RT, protect from light.
In solvent -80°C, 1 year , -20°C, 6 months
Biological Activity
Description
IC50 & Target
[3]|
TNF-α |
IL-6 |
IL-5 |
IL-17 |
In Vitro
Centella asiatica extract (100-500 µg/mL; 1 h pre-incubation; 24 h stimulation with IFN-γ/TNF-α) dose-dependently reduces the expression levels of pro-inflammatory proteins COX-2 and IL-6 in IFN-γ/TNF-α-stimulated human keratinocyte HaCaT cells[3].
Centella asiatica extract (200 μg/mL; pre-incubated for 30 min prior to 24 h LPS stimulation) alters the mRNA expression of Il10 in RAW264.7 mouse macrophages stimulated with low glucose and LPS (HY-D1056)[4].
Centella asiatica extract (200 μg/mL; 30 min pre-incubation prior to 24 h LPS stimulation) inhibits the polarization of high glucose plus LPS-stimulated RAW264.7 mouse macrophages toward pro-inflammatory M1 macrophages by reducing the mRNA expression of Ccl2, Il6, Il1b and Tnf[4].
Centella asiatica extract (CA) (10-1000 µg/mL; 24 h) shows no cytotoxicity against HaCaT human keratinocytes at concentrations up to 500 µg/mL, while cytotoxicity is observed starting from the concentration of 600 µg/mL[3].
Centella asiatica extract (100-500 µg/mL) has detectable polyphenol and flavonoid contents, and exhibits concentration-dependent ABTS and DPPH free radical scavenging activity[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HaCaT human keratinocytes
-
Concentration:10, 40, 70, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000 µg/mL
-
Incubation Time:24 h
-
Result:Showed no cytotoxicity in HaCaT cells at concentrations ranging from 10 µg/mL to 500 µg/mL, with cell viability remaining above 100% relative to the control.
Reduced cell viability to 48.46% at 600 µg/mL CA.
-
Cell Line:IFN-γ/TNF-α-stimulated HaCaT human keratinocytes
-
Concentration:100, 300, 500 µg/mL
-
Incubation Time:1 h pre-incubation; 24 h stimulation with IFN-γ/TNF-α
-
Result:Reduced COX-2 expression to 0.9-fold, 0.6-fold, and 0.4-fold relative to the stimulated control at 100 µg/mL, 300 µg/mL, and 500 µg/mL CA, respectively.
Reduced IL-6 expression to 0.9-fold, 0.4-fold, and 0.3-fold relative to the stimulated control at 100 µg/mL, 300 µg/mL, and 500 µg/mL CA, respectively.
-
Cell Line:RAW264.7 mouse macrophage cell line (high glucose condition)
-
Concentration:200 μg/mL
-
Incubation Time:30 min pre-incubation prior to 24 h LPS stimulation
-
Result:Alleviated mRNA relative expression levels of the M1 pro-inflammatory markers Ccl2, Il6, Il1b, and Tnf.
Had no effect on Il10 and Mgl1 mRNA expression levels.
Showed inconsistent elevation of Cd206 mRNA expression under high glucose+LPS conditions.
In Vivo
Centella asiatica extract (80 µg/cm2; topical skin administration; once daily; 14 days; 200 mg/kg; oral administration; once daily; 14 days) alleviates DNCB-induced atopic dermatitis symptoms in BALB/c mice, including ear swelling, lymph node enlargement, skin hyperplasia, mast cell infiltration, and the expression of pro-inflammatory cytokines and signaling proteins[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Danio rerio (larvae, 0-2 hours post-fertilization to 9 days post-fertilization, hypoxic-ischemic injury model)[2]
-
Dosage:1.25 μg/mL; 2.5 μg/mL; 5 μg/mL
-
Administration:continuous; 6 days
-
Result:Increased average BDNF expression to 36.2 at 3 days post-fertilization and 35.92 at 9 days post-fertilization with 1.25 μg/mL, compared to hypoxic control's 34.66 and 35.33 respectively.
Increased average BDNF expression to 34.82 at 3 days post-fertilization and 36.26 at 9 days post-fertilization with 2.5 μg/mL, compared to hypoxic control's 34.66 and 35.33 respectively.
Increased average BDNF expression to 36.19 at 3 days post-fertilization and decreased it to 34.09 at 9 days post-fertilization with 5 μg/mL, compared to hypoxic control's 34.66 and 35.33 respectively.
Decreased average VGLUT1 expression to 27.54 at 3 days post-fertilization and increased it to 32.95 at 9 days post-fertilization with 1.25 μg/mL, compared to hypoxic control's 32.64 and 32.23 respectively.
Increased average VGLUT1 expression to 32.65 at 3 days post-fertilization and decreased it to 31.19 at 9 days post-fertilization with 2.5 μg/mL, compared to hypoxic control's 32.64 and 32.23 respectively.
Increased average VGLUT1 expression to 33.45 at 3 days post-fertilization and decreased it to 32.08 at 9 days post-fertilization with 5 μg/mL, compared to hypoxic control's 32.64 and 32.23 respectively.
-
Animal Model:BALB/c (8-week-old female, DNCB-induced atopic dermatitis)[3]
-
Dosage:80 µg/cm2 (skin local); 200 mg/kg (p.o.)
-
Administration:skin local; daily; 14 days; p.o.; daily; 14 days
-
Result:Reduced ear thickness 1.3-fold (80 µg/cm2 skin local) and 1.2-fold (200 mg/kg oral) relative to untreated DNCB-induced mice.
Reduced lymph node weight 1.6-fold in both treatment groups compared to untreated DNCB-induced mice.
Reduced epidermal thickness 2.7-fold (skin local) and 1.9-fold (oral) relative to untreated DNCB-induced mice.
Reduced dermal thickness 10.1-fold (skin local) and 5.9-fold (oral) relative to untreated DNCB-induced mice.
Reduced mast cell infiltration 4.4-fold (skin local) and 3.7-fold (oral) compared to untreated DNCB-induced mice.
Reduced mRNA expression of TNF-α 5.6-fold (skin local) and 12.9-fold (oral), IL-5 5.6-fold (skin local) and 11.5-fold (oral), IL-10 3.2-fold (skin local) and 9.5-fold (oral), IL-6 12.6-fold (skin local) and 1.7-fold (oral), as well as iNOS, COX-2, and CXCL9 relative to untreated DNCB-induced mice.
Reduced protein expression of TNF-α 2.7-fold (skin local) and 1.6-fold (oral), COX-2 2.9-fold (skin local) and 1.7-fold (oral), MAC-1 1.5-fold (skin local) and 1.6-fold (oral), and IL-6 3.4-fold in both groups relative to untreated DNCB-induced mice.
Suppressed p-p38 protein expression 1.4-fold (skin local) and 1.7-fold (oral) relative to untreated DNCB-induced mice.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 84696-21-9
-
Appearance Powder
-
SMILES
[Centella asiatica extract]
-
Structure Classification
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
RT, protect from light
In solvent -80°C 1 year -20°C 6 months
Solvent & Solubility
In Vitro:
DMSO : 50 mg/mL (ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 50 mg/mL (Need ultrasonic)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 5 mg/mL; Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 5 mg/mL; Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Protocols
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
LPS-Induced Endotoxemia/Systemic Inflammation
Lipopolysaccharide (LPS)-induced endotoxemia is a widely used in vivo model of acute systemic inflammation in which LPS, a Gram-negative bacterial endotoxin, activates innate immune signaling primarily through TLR4, leading to rapid and transient induction of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β in circulation and tissues. This cytokine surge is commonly used as a measurable readout of systemic inflammatory activation and immune dysregulation, and is typically assessed within hours after intraperitoneal LPS administration in mouse models of endotoxemia. The model captures key features of systemic inflammatory response syndrome, including cytokine release, immune cell activation, and downstream tissue responses, and has been used to evaluate anti-inflammatory interventions such as cytokine modulation, lipid mediators, and immune cell-targeting therapies.
-
Large-size fat particle sorting
Large-size fat particle sorting is widely used to isolate cells up to 200 μm in diameter. Single-cell flow sorting will allow greater insight into adipocyte heterogeneity by identifying gene expression, protein composition, and metabolic signatures at the single-cell level.
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
-
TPA/Croton Oil Ear Edema and Dermatitis
The TPA (12-O-tetradecanoylphorbol-13-acetate) and croton oil-induced mouse ear edema model is a well-established acute cutaneous inflammation system used to evaluate topical anti-inflammatory activity by measuring edema formation, neutrophil infiltration, vascular permeability, and cytokine-mediated skin responses in vivo. The inflammatory response is triggered by topical application of phorbol esters (TPA) or croton oil constituents, leading to rapid activation of protein kinase C signaling, leukocyte recruitment, and increased vascular permeability, which can be quantified by ear thickness, weight, dye extravasation, and biochemical markers such as myeloperoxidase (MPO) activity and pro-inflammatory mediators in ear tissue homogenates. This model is widely used for screening anti-inflammatory agents, where reductions in edema and inflammatory biomarkers reflect suppression of acute dermal inflammation and immune cell infiltration. Histological evaluation typically confirms epidermal
-
Primary monocyte-to-macrophage differentiation
Primary human monocytes can be differentiated ex vivo into monocyte-derived macrophages by culturing purified blood monocytes for approximately 5-7 days in macrophage-supporting cytokine conditions; M-CSF commonly yields CD14^high/CD163^high macrophages, while GM-CSF yields a phenotypically distinct macrophage population, so the cytokine condition should be chosen according to the downstream model. The readout of successful differentiation is a combined change in morphology, adherence, surface phenotype, and function: differentiated macrophages become adherent, enlarge, acquire macrophage-associated markers such as CD14, CD68, CD163, CD206, or HLA-DR depending on culture condition, and show increased phagocytic capacity compared with starting monocytes.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked
-
Senescence-associated β-galactosidase staining
Senescence-associated β-galactosidase staining detects β-galactosidase activity that is histochemically visible at pH 6. 0 in senescent cells, where X-gal cleavage produces an insoluble blue precipitate observable by bright-field microscopy. This activity reflects increased lysosomal β-galactosidase/lysosomal mass rather than a senescence-essential enzyme, because GLB1 depletion or genetic lysosomal β-galactosidase deficiency can abolish SA-β-gal staining while cells still undergo senescence. SA-β-gal was originally reported in senescent but not presenescent fibroblasts and keratinocytes, absent from quiescent fibroblasts and terminally differentiated keratinocytes, and increased with donor age in human skin samples. Because SA-β-gal can also appear in some non-senescent or tissue-specific contexts, interpretation should be paired with experimental controls and, when possible, independent senescence markers.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)